Clinical Trials in Bunkyō City, Japan
63 recruiting
Showing 1–20 of 52 trials
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled33 locationsNCT07258511
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled29 locationsNCT07155226
Recruiting
Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled842 locationsNCT06307652
Recruiting
Phase 2Phase 3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial CancerBladder Cancer
Daiichi Sankyo630 enrolled79 locationsNCT07129993
Recruiting
Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled135 locationsNCT06549595
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled33 locationsNCT06916806
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Prurigo Nodularis
Incyte Corporation330 enrolled121 locationsNCT06516965
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Locally Advanced Head and Neck Squamous Cell CarcinomaAged
Johnson & Johnson Enterprise Innovation Inc.500 enrolled189 locationsNCT04892173
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled104 locationsNCT06919965
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled261 locationsNCT05552222
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled108 locationsNCT07391657
Recruiting
Phase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease
Eli Lilly and Company48 enrolled10 locationsNCT06297590